A clinical study of samuraciclib (CT7001), a first-in-class, oral, selective inhibitor of CDK7, in patients with advanced triple negative breast cancer (TNBC)Sacha J. Howell,Laura M. Kenny,Simon Lord,Matthew G. Krebs,Tobias Arkenau,Richard Baird,Iain R. MacPherson,Ash Bahl,Glen Clack,Edward Ainscow,Anthony G. M. Barrett,Paul A. Dickinson,Matthew J. Fuchter,Manfred Lehnert,Simak Ali,Stuart McIntosh, Charles CoombesCANCER RESEARCH（2022）引用 0|浏览21暂无评分AI 理解论文溯源树样例生成溯源树，研究论文发展脉络Chat Paper正在生成论文摘要
